SFRP2 and colonic neoplasm: At the same time, SFRP2 methylation was found to occur high-frequent in colon cancer (83–90%) [33,19], which may have forced the establishment of SFRP2 methylation as a promising sensitive screening marker for the stool-based detection of colorectal cancer and premalignant lesions [34-36].